By targeting Alox5 with zileuton (an Alox5 inhibitor), the spontaneous metastatic rate and the seeding capacity of cancer cells into the lungs were greatly reduced in a metastatic breast cancer mouse model [115]. Here, ALOX5 is linked to breast carcinoma.